PD-1/PD-L1
PD-1/PD-L1 inhibitors are immune checkpoint inhibitors that block the interaction between the programmed cell death protein 1 (PD-1) on T cells and its ligand PD-L1 on cancer cells. This interaction normally suppresses the immune response and allows cancer cells to evade immune detection. By inhibiting PD-1/PD-L1, these inhibitors enhance the immune system's ability to recognize and destroy cancer cells, inducing apoptosis and tumor regression. PD-1/PD-L1 inhibitors are critical in immunotherapy research and cancer treatment. At CymitQuimica, we offer a range of high-quality PD-1/PD-L1 inhibitors to support your research in immuno-oncology, apoptosis, and cancer therapy.
Found 125 products of "PD-1/PD-L1"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Sintilimab
CAS:<p>Sintilimab (IBI308), an IgG4 monoclonal antibody, blocks PD-1, enhancing T-cell anti-tumor response; treats Hodgkin's, lung, and esophageal cancers.</p>Purity:> 95%Color and Shape:LiquidMolecular weight:144.04 kDaDurvalumab
CAS:<p>Durvalumab is a humanized antibody for cancer, inhibiting PD-L1/PD-1 and CD80 interactions at very low concentrations.</p>Purity:SDS-PAGE:97.2%;SEC-HPLC:95.3%Color and Shape:LiquidMolecular weight:146.03 kDaEzabenlimab
CAS:<p>Ezabenlimab (BI-754091) is an anti-PD-1 mAb, Kd 6 nM, blocks PD-1/PD-Ls, boosts T-cell IFN-γ, inhibits tumors in vivo.</p>Purity:99.1% (SDS-PAGE); 96.9% (SEC-HPLC) - 99.1% (SDS-PAGE); 96.9% (SEC-HPLC)Color and Shape:LiquidPenpulimab
CAS:<p>Penpulimab is a monoclonal antibody targeting PD-1 with antitumor activity, used in studies of pancreatic cancer.</p>Purity:96.8% (SEC-HPLC) - 96.8% (SEC-HPLC)Color and Shape:LiquidSpartalizumab
CAS:<p>"Spartalizumab (PDR001), a humanized IgG4 monoclonal antibody, targets PD-1 to inhibit PD-L1/L2 interactions, useful in ATC research."</p>Purity:SDS-PAGE:95.2%;SEC-HPLC:96.3%Color and Shape:LiquidMolecular weight:145.74 kDaBudigalimab
CAS:<p>Budigalimab (ABBV 181) is a humanized monoclonal antibody targeting PD-1 with potential antitumor activity.</p>Purity:97% (SDS-PAGE); 98.8% (SEC-HPLC) - 97% (SDS-PAGE); 98.8% (SEC-HPLC)Color and Shape:LiquidAUNP-12 acetate
<p>AUNP-12 acetate is a polypeptide inhibitor of PD-1 that is equivalent to PD-1 and PD-2 in inhibiting lymphocyte proliferation and effector fuction, in addition</p>Formula:C144H230N40O50Purity:95.07%Color and Shape:SolidMolecular weight:3321.61Dostarlimab
CAS:<p>Dostarlimab (TSR-042) is an immune checkpoint inhibitor targeting PD-1, blocking its interaction with its ligands PD-L1 and PD-L2.</p>Purity:>95%Color and Shape:LiquidZimberelimab
CAS:<p>Zimberelimab (GLS-010) is a humanized antibody targeting PD-1, with anticancer activity.</p>Purity:95%Color and Shape:LiquidTislelizumab
CAS:<p>Tislelizumab, a PD-1 receptor monoclonal antibody, reduces Fcγ interaction and T cell clearance in advanced squamous NSCLC research.</p>Purity:95.07%Color and Shape:LiquidBMS-1001 hydrochloride
CAS:<p>BMS-1001 hydrochloride is an orally active inhibitor of human PD-1/PD-L1 immune checkpoint with low-toxicity in cells.BMS-1001 alleviates the inhibitory effect</p>Formula:C35H35ClN2O7Purity:97.36%Color and Shape:SolidMolecular weight:631.11PD-1/PD-L1-IN-50
<p>Compound LG-12, known chemically as PD-1/PD-L1-IN-50, is an inhibitor of PD-1/PD-L1. It enhances the secretion of IFN-γ, promotes the activation of CD8+ T cells, and activates T cell-mediated anti-tumor immunity.</p>Color and Shape:Odour SolidLatikafusp
CAS:<p>Latikafusp (AMG 256) is a fusion protein that is a PD-1 blocker and IL-21R agonist with antitumor activity.</p>Purity:97.1% (SDS-PAGE); 97.4% (SEC-HPLC) - 97.1% (SDS-PAGE); 97.4% (SEC-HPLC)Color and Shape:LiquidCamrelizumab
CAS:<p>Camrelizumab (SHR-1210) is a human IgG4-κ monoclonal antibody with high affinity and directed against PD-1.Camrelizumab binds PD-1 with a binding affinity of up</p>Purity:95% - 98.6%Color and Shape:LiquidMolecular weight:143.7 kDaHuman PD-L1 inhibitor IV
CAS:<p>PD-L1 inhibitor IV, a polypeptide, competitively blocks hPD-1 with a Kd of 1.38 μM, preventing hPD-1/hPD-L1 interaction.</p>Formula:C80H113N25O27Color and Shape:SolidMolecular weight:1856.932Moflerafusp alfa
CAS:<p>Moflerafusp alfa is a fusion protein that targets the human signal-regulatory protein alpha (SIRPα) variant V2 D1 domain and human programmed death-ligand 1 (PD-L1). It shows potential for research in various cancer treatments.</p>Color and Shape:LiquidEciskafusp alfa
CAS:<p>Eciskafusp alfa, a cis-targeted IL2v immunocytokine, acts on programmed cell death 1 (PDCD1, commonly known as PD-1), preferentially targeting antigen-specific</p>Purity:98%Color and Shape:SolidPidilizumab
CAS:<p>Pidilizumab (CT-011), a humanized IgG1κ anti-PD-1 monoclonal antibody, serves as a DLL1 antagonist with potential applications in researching hematologic</p>Purity:98%Color and Shape:LiquidSotiburafusp alfa
CAS:<p>Sotiburafusp alfa is a humanized bispecific fusion protein comprising a VEGFR-1 extracellular domain fragment (129-228, 1-100 in the current sequence) connected</p>Purity:98%Color and Shape:SolidOPBP-1
<p>OPBP-1 is a D-peptide developed through phage display screening, molecular docking, and molecular dynamics simulations. It exhibits high stability, strong antitumor activity, and oral bioavailability. OPBP-1 selectively binds to the PD-L1 protein, significantly blocking the interaction between PD-1 and PD-L1, which helps restore and enhance T lymphocyte function while reducing the proportion of myeloid-derived suppressor cells (MDSCs), counteracting tumor-induced immune evasion. OPBP-1 is applicable for research in cancer immunotherapy.</p>Formula:C64H92N20O19SMolecular weight:1476.65683PROTAC PD-L1 degrader-1
<p>PROTACPD-L1 degrader-1 is a CRBN-based PD-L1-PROTAC degrader with significant PD-L1 protein degradation capacity. It demonstrates strong PD-L1 degradation activity in 4T1 cells, with a DC50 of 0.609 μM. This compound is applicable to breast cancer research.</p>Ledostomig
CAS:<p>Ledostomig is an immunoglobulin (H-γ1-scFv-L-κ) dimer monoclonal antibody that targets human neurotensin receptor type 5 (NTS5) and programmed death-1 (PD-1). It shows potential for research in various cancer types.</p>Color and Shape:LiquidTPP-1 TFA
<p>TPP-1 TFA is a high-affinity PD-L1 inhibitor (KD=95nM) that boosts T-cell function to curb tumor growth.</p>Formula:C109H151F3N34O34S2Color and Shape:SolidMolecular weight:2602.69Zeluvalimab
CAS:<p>Zeluvalimab (AMG-404) is a monoclonal antibody designed to target the PD-1 receptor, and is utilized in cancer research [1].</p>Color and Shape:LiquidPM-8002
<p>PM-8002 is a bispecific antibody that targets PD-L1 and VEGF-A. It is applicable for research on solid tumors.</p>Color and Shape:Odour LiquidFinotonlimab
<p>Finotonlimab (SCT-I10A), a humanized IgG PD-1 monoclonal antibody, shows potential in the research of solid tumors or lymphomas [1].</p>Color and Shape:Odour LiquidManelimab
CAS:<p>Manelimab is a monoclonal antibody that inhibits programmed death-ligand 1 ( PD-L1 ) [1] .</p>Color and Shape:LiquidAnti-Mouse PD-1 (LALA-PG) Antibody (RMP1-14)
<p>Anti-MousePD-1(LALA-PG) Antibody (RMP1-14) is an IgG2a, κ antibody inhibitor derived from mice that targets and inhibits mouse PD-1.</p>Color and Shape:Odour LiquidLorigerlimab
CAS:<p>Lorigerlimab (MGD019) is a bispecific IgG4 DART that blocks PD-1/CTLA-4, enhancing T-cells for mCRPC research.</p>Color and Shape:LiquidAnti-Mouse PD-1 Antibody (D265A) Antibody (RMP1-14)
<p>Anti-Mouse PD-1 Antibody (D265A) is an IgG2a, κ antibody inhibitor derived from mice, specifically targeting mouse PD-1.</p>Color and Shape:Odour LiquidPD-1/PD-L1-IN-52
<p>PD-1/PD-L1-IN-52 (Compound Ⅲ-5) is an orally active inhibitor of PD-1/PD-L1 interaction, exhibiting an IC50 of 109.9 nM. It demonstrates antitumor activity in a C57BL/6 mouse model of MC38 colon carcinoma cells expressing human PD-1, achieving a tumor growth inhibition (TGI) rate of 49.6%.</p>Color and Shape:Odour SolidSudubrilimab
<p>Sudubrilimab (HS636) is an IgG1-κ monoclonal antibody targeting PDL1, fused with TGFBR2-ECD to block PD-1/PDL1 and TGF-β in tumors.</p>Color and Shape:Odour LiquidHuman PD-L1 inhibitor II
CAS:<p>Human PD-L1 inhibitor II is a potent PD-L1 inhibitor with anti-cancer activity.</p>Formula:C103H151N25O30Color and Shape:SolidMolecular weight:2219.486Betifisolimab
CAS:<p>Betifisolimab (MSB-2311) is a humanized antibody targeting PD-L1 for solid tumors and blood cancer research.</p>Color and Shape:LiquidOpucolimab
CAS:<p>Opucolimab is a human antibody targeting PD-L1, used in advanced solid tumor research and antibody-drug conjugate synthesis.</p>Color and Shape:LiquidPD-1/PD-L1-IN-49
<p>PD-1/PD-L1-IN-49 (compound 1c) is a potent inhibitor of PD-1/PD-L1 with an IC50 of 77 nM. This compound can activate Jurkat T cells and effectively block the PD-1/PD-L1 immune checkpoint.</p>Formula:C27H32N4O5Color and Shape:SolidMolecular weight:492.567Human PD-L1 inhibitor III
CAS:<p>Human PD-L1 inhibitor III is a human PD-L1 inhibitor.</p>Formula:C97H155N29O29SColor and Shape:SolidMolecular weight:2223.54AUNP-12
CAS:<p>AUNP-12, a new immune checkpoint modulator, is an inhibitor of the PD-1 pathway.</p>Formula:C142H226N40O48Purity:98%Color and Shape:SolidMolecular weight:3261.55PD-L1-IN-5
<p>PD-L1-IN-5 (X22) is an orally active PD-L1 inhibitor with an IC50 of 785.6 nM, demonstrating antitumor activity in vivo.</p>Lodapolimab
CAS:<p>Lodapolimab (LY3300054) is an IgGλ anti- PD-1 monoclonal antibody [1] .</p>Color and Shape:LiquidPimivalimab
CAS:<p>Pimivalimab (JTX-4014), a PD-1 inhibitor, is utilized in solid tumor research [1].</p>Color and Shape:LiquidPD-L1 inhibitory peptide
CAS:<p>PD-L1inhibitory peptide is an inhibitor peptide that targets the programmed cell death ligand 1 (PD-L1). By binding to PD-L1, it lifts immune suppression and restores the anti-tumor activity of T cells. PD-L1inhibitory peptide holds promise for use in tumor research.</p>Formula:C96H135N21O23SColor and Shape:SolidMolecular weight:1983.29PD-L1/VISTA-IN-2
<p>PD-L1/VISTA-IN-2 (Compound S8) is an orally active dual inhibitor targeting PD-L1 and VISTA, with an IC50 of 1.4 μM for PD-L1 and a KD of 2.1 μM for VISTA. This compound can activate the tumor immune microenvironment, exerting anticancer effects.</p>Formula:C22H22N2O3Color and Shape:SolidMolecular weight:362.42Balstilimab
CAS:<p>Balstilimab (AGEN2034) is a fully human monoclonal IgG4 antibody against PD-1 [1] .</p>Color and Shape:LiquidIparomlimab
CAS:<p>Iparomlimab: anti-PD-1 IgG4κ antibody, targets PSB103 γ4/κ-chains, forms dimers, used in cancer research.</p>Color and Shape:LiquidPD-1/PD-L1-IN-9
CAS:<p>PD-1/PD-L1-IN-9, with an IC50 of 3.8 nM, is a potent and orally active inhibitor of the PD-1/PD-L1 interaction.</p>Formula:C22H24N2O2Purity:99.92%Color and Shape:SolidMolecular weight:348.44TQB-2858
<p>TQB-2858 is a bifunctional fusion protein composed of an anti-PD-L1 monoclonal antibody fused with the extracellular domain of the TGF-β receptor. It exhibits high affinity for PD-L1, TGF-β1, and TGF-β3, and demonstrates a high target occupancy rate for PD-L1. TQB-2858 can be used in research on osteosarcoma and alveolar soft part sarcoma (ASPS).</p>Color and Shape:Odour LiquidPD-1/PD-L1-IN-48
<p>PD-1/PD-L1-IN-48 (compound HD10) is an effective inhibitor of the PD-1/PD-L1 interaction, exhibiting an IC50 of 3.1 nM. It plays a vital role in cancer research.</p>Color and Shape:Odour SolidHuman PD-L1 inhibitor I
CAS:<p>Human PD-L1 inhibitor I, a peptide, blocks PD-L1/PD-1 interaction with 3.39 μM affinity.</p>Formula:C110H152N26O32Color and Shape:SolidMolecular weight:2350.576BMSpep-57
CAS:<p>BMSpep-57: Macrocyclic peptide, inhibits PD-1/PD-L1, IC50=7.68 nM, binds PD-L1 (Kd=19 nM/MST, 19.88 nM/SPR), boosts T cell IL-2 in PBMCs.</p>Formula:C89H126N24O19SColor and Shape:SolidMolecular weight:1868.2
